177 related articles for article (PubMed ID: 34563875)
1. Capacity Building for Primary Stroke Prevention Teams in Children Living With Sickle Cell Anemia in Africa.
Ghafuri DL; Covert Greene B; Musa B; Gambo A; Sani A; Abdullahi S; Wudil BJ; Bello-Manga H; Gambo S; Ghafuri M; Cassell H; Neville K; Kirkham F; Kassim AA; Aliyu MH; DeBaun MR; Jordan LC
Pediatr Neurol; 2021 Dec; 125():9-15. PubMed ID: 34563875
[TBL] [Abstract][Full Text] [Related]
2. Primary Prevention of Stroke in Children With Sickle Cell Anemia in Nigeria: Protocol for a Mixed Methods Implementation Study in a Community Hospital.
Bello-Manga H; Haliru L; Ahmed KA; Tabari AM; Farouk BU; Bahago GY; Kazaure AS; Muhammad AS; Gwarzo SA; Baumann AA; DeBaun MR; King AA
JMIR Res Protoc; 2022 Jun; 11(6):e37927. PubMed ID: 35700018
[TBL] [Abstract][Full Text] [Related]
3. Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial).
Galadanci NA; Umar Abdullahi S; Vance LD; Musa Tabari A; Ali S; Belonwu R; Salihu A; Amal Galadanci A; Wudil Jibir B; Bello-Manga H; Neville K; Kirkham FJ; Shyr Y; Phillips S; Covert BV; Kassim AA; Jordan LC; Aliyu MH; DeBaun MR
Am J Hematol; 2017 Aug; 92(8):780-788. PubMed ID: 28439953
[TBL] [Abstract][Full Text] [Related]
4. Stroke Prevention with Hydroxyurea Enabled through Research and Education: A Phase 2 Primary Stroke Prevention Trial in Sub-Saharan Africa.
Smart LR; Ambrose EE; Balyorugulu G; Songoro P; Shabani I; Komba P; Charles M; Howard TA; McElhinney KE; O'Hara SM; Odame J; Nakafeero M; Adams J; Stuber SE; Lane A; Latham TS; Makubi AN; Ware RE
Acta Haematol; 2023; 146(2):95-105. PubMed ID: 35977532
[TBL] [Abstract][Full Text] [Related]
5. Primary prevention of stroke in children with sickle cell anemia in sub-Saharan Africa: rationale and design of phase III randomized clinical trial.
Abdullahi SU; Wudil BJ; Bello-Manga H; Musa AB; Gambo S; Galadanci NA; Aminu H; Tijjani Gaya A; Sanusi S; Tabari MA; Galadanci A; Borodo A; Abba MS; Dambatta AH; Haliru L; Gambo A; Cassell H; Rodeghier M; Ghafuri DL; Covert Greene BV; Neville K; Kassim AA; Kirkham F; Trevathan E; Jordan LC; Aliyu MH; DeBaun MR
Pediatr Hematol Oncol; 2021 Feb; 38(1):49-64. PubMed ID: 33236662
[TBL] [Abstract][Full Text] [Related]
6. Stroke Avoidance for Children in REpública Dominicana (SACRED): Protocol for a Prospective Study of Stroke Risk and Hydroxyurea Treatment in Sickle Cell Anemia.
Jeste ND; Sánchez LM; Urcuyo GS; Bergés ME; Luden JP; Stuber SE; Latham TS; Mena R; Nieves RM; Ware RE
JMIR Res Protoc; 2017 Jun; 6(6):e107. PubMed ID: 28576754
[TBL] [Abstract][Full Text] [Related]
7. Capacity building and stroke risk assessment in Nigerian children with sickle cell anaemia.
Soyebi K; Adeyemo T; Ojewunmi O; James F; Adefalujo K; Akinyanju O
Pediatr Blood Cancer; 2014 Dec; 61(12):2263-6. PubMed ID: 25174615
[TBL] [Abstract][Full Text] [Related]
8. PRIMARY STROKE PREVENTION IN CHILDREN WITH SICKLE CELL ANEMIA LIVING IN AFRICA: THE FALSE CHOICE BETWEEN PATIENT-ORIENTED RESEARCH AND HUMANITARIAN SERVICE.
Debaun MR; Galadanci NA; Kassim AA; Jordan LC; Phillips S; Aliyu MH
Trans Am Clin Climatol Assoc; 2016; 127():17-33. PubMed ID: 28066035
[TBL] [Abstract][Full Text] [Related]
9. PRIMARY STROKE PREVENTION IN CHILDREN WITH SICKLE CELL ANEMIA LIVING IN AFRICA: THE FALSE CHOICE BETWEEN PATIENT-ORIENTED RESEARCH AND HUMANITARIAN SERVICE-PART II.
Debaun MR
Trans Am Clin Climatol Assoc; 2022; 132():236-248. PubMed ID: 36196180
[TBL] [Abstract][Full Text] [Related]
10. Hydroxyurea lowers transcranial Doppler flow velocities in children with sickle cell anaemia in a Nigerian cohort.
Lagunju I; Brown BJ; Sodeinde O
Pediatr Blood Cancer; 2015 Sep; 62(9):1587-91. PubMed ID: 25847050
[TBL] [Abstract][Full Text] [Related]
11. Practice patterns for stroke prevention using transcranial Doppler in sickle cell anemia: DISPLACE Consortium.
Schlenz AM; Phillips S; Mueller M; Melvin C; Adams RJ; Kanter J;
Pediatr Blood Cancer; 2020 Apr; 67(4):e28172. PubMed ID: 31925913
[TBL] [Abstract][Full Text] [Related]
12. Primary stroke prevention in Nigerian children with sickle cell disease (SPIN): challenges of conducting a feasibility trial.
Galadanci NA; Abdullahi SU; Tabari MA; Abubakar S; Belonwu R; Salihu A; Neville K; Kirkham F; Inusa B; Shyr Y; Phillips S; Kassim AA; Jordan LC; Aliyu MH; Covert BV; DeBaun MR
Pediatr Blood Cancer; 2015 Mar; 62(3):395-401. PubMed ID: 25399822
[TBL] [Abstract][Full Text] [Related]
13. The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation.
Cherry MG; Greenhalgh J; Osipenko L; Venkatachalam M; Boland A; Dundar Y; Marsh K; Dickson R; Rees DC
Health Technol Assess; 2012; 16(43):1-129. PubMed ID: 23140544
[TBL] [Abstract][Full Text] [Related]
14. Translating research to usual care of children with sickle cell disease in Northern Nigeria: lessons learned from the SPRING Trial Team.
Bello-Manga H; Haliru L; Tabari AM; Farouk B; Suleiman A; Bahago GY; Sani AM; Bauman AA; DeBaun MR; King AA
BMC Res Notes; 2022 Jan; 15(1):1. PubMed ID: 34983646
[TBL] [Abstract][Full Text] [Related]
15. Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
Estcourt LJ; Kimber C; Hopewell S; Trivella M; Doree C; Abboud MR
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD012389. PubMed ID: 32250453
[TBL] [Abstract][Full Text] [Related]
16. Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial.
Abdullahi SU; Jibir BW; Bello-Manga H; Gambo S; Inuwa H; Tijjani AG; Idris N; Galadanci A; Hikima MS; Galadanci N; Borodo A; Tabari AM; Haliru L; Suleiman A; Ibrahim J; Greene BC; Ghafuri DL; Rodeghier M; Slaughter JC; Kirkham FJ; Neville K; Kassim A; Trevathan E; Jordan LC; Aliyu MH; DeBaun MR
Lancet Haematol; 2022 Jan; 9(1):e26-e37. PubMed ID: 34971579
[TBL] [Abstract][Full Text] [Related]
17. Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial.
Ambrose EE; Latham TS; Songoro P; Charles M; Lane AC; Stuber SE; Makubi AN; Ware RE; Smart LR
Lancet Haematol; 2023 Apr; 10(4):e261-e271. PubMed ID: 36870358
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia.
Zimmerman SA; Schultz WH; Burgett S; Mortier NA; Ware RE
Blood; 2007 Aug; 110(3):1043-7. PubMed ID: 17429008
[TBL] [Abstract][Full Text] [Related]
19. Stroke and stroke prevention in sickle cell anemia in developed and selected developing countries.
Bhattacharya P; Sarmah D; Dave KR; Goswami A; Watanabe M; Wang X; Kalia K; Plesnila N; Yavagal DR; Alvarez O
J Neurol Sci; 2021 Aug; 427():117510. PubMed ID: 34077859
[TBL] [Abstract][Full Text] [Related]
20. Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews.
Fortin PM; Hopewell S; Estcourt LJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012082. PubMed ID: 30067867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
